Palforzia: Managing peanut oral immunotherapy, co-morbidities and risk of anaphylaxis

被引：0
|
作者：
Saych, Lauren [1 ]
Cragg, Olivia [1 ]
Sharma, Vibha [1 ]
机构：
[1] Royal Manchester Childrens Hosp, Manchester, Lancs, England
来源：
CLINICAL AND EXPERIMENTAL ALLERGY | 2023年 / 53卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
A076
引用
收藏
页码：1100 / 1101
页数：2
相关论文
共 50 条
  • [21] Suicide Risk and Mental Health Co-morbidities in a Probationer Population
    Cardarelli, Roberto
    Balyakina, Elizabeth
    Malone, Kendra
    Fulda, Kimberly G.
    Ellison, Michael
    Sivernell, Ron
    Shabu, Tanjina
    COMMUNITY MENTAL HEALTH JOURNAL, 2015, 51 (02) : 145 - 152
  • [22] Peanut oral immunotherapy protecting a young captive in Gaza from anaphylaxis
    Elizur, Arnon
    Goldberg, Michael R.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2024, 133 (03) : 341 - 342
  • [23] Anaphylaxis during Peanut Oral Immunotherapy: Looking beyond dose escalation
    Blackman, Andrea C.
    Staggers, Kristen A.
    Anagnostou, Aikaterini
    PEDIATRIC ALLERGY AND IMMUNOLOGY, 2022, 33 (12)
  • [24] Grass pollen allergy as an anaphylaxis cofactor during peanut oral immunotherapy
    Chua, Gilbert T.
    Chan, Edmond S.
    Soller, Lianne
    Cameron, Scott B.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2021, 127 (02) : 263 - 264
  • [25] Brain inflammation is induced by co-morbidities and risk factors for stroke
    Drake, Caroline
    Boutin, Herve
    Jones, Matthew S.
    Denes, Adam
    McColl, Barry W.
    Selvarajah, Johann R.
    Hulme, Sharon
    Georgiou, Rachel F.
    Hinz, Rainer
    Gerhard, Alexander
    Vail, Andy
    Prenant, Christian
    Julyan, Peter
    Maroy, Renaud
    Brown, Gavin
    Smigova, Alison
    Herholz, Karl
    Kassiou, Michael
    Crossman, David
    Francis, Sheila
    Proctor, Spencer D.
    Russell, James C.
    Hopkins, Stephen J.
    Tyrrell, Pippa J.
    Rothwell, Nancy J.
    Allan, Stuart M.
    BRAIN BEHAVIOR AND IMMUNITY, 2011, 25 (06) : 1113 - 1122
  • [26] Influence of co-morbidities and co-medications on safety and tolerability in the buildup phase of venom immunotherapy
    Bauer, A.
    Bernkopf, K.
    Spornraft-Ragaller, P.
    ALLERGY, 2012, 67 : 414 - 414
  • [27] Risk factors, co-morbidities, and co-medications in cardioprotection: Importance for translation
    Schulz, Rainer
    Andreadou, Ioanna
    Hausenloy, Derek J.
    Ferdinandy, Peter
    BRITISH JOURNAL OF PHARMACOLOGY, 2020, 177 (23) : 5249 - 5251
  • [28] EFFECT OF CO-MORBIDITIES ON FRACTURE RISK: FINDINGS FROM THE GLOW STUDY
    Dennison, E. M.
    Premaor, M.
    Flahive, J.
    Siris, E. S.
    Gehlbach, S.
    Adachi, J. D.
    Boonen, S.
    Chapurlat, R.
    Delmas, P.
    Diez-Perez, A.
    Hooven, F. H.
    LaCroix, A.
    Netelenbos, J. C.
    Pfeilschifter, J.
    Rossini, M.
    Roux, C.
    Saag, K. G.
    Sambrook, P.
    Silverman, S.
    Watts, N. B.
    Greenspan, S. L.
    Compston, J.
    Cooper, C.
    OSTEOPOROSIS INTERNATIONAL, 2011, 22 : S529 - S530
  • [29] Low back pain risk factors in a large rural Australian Aboriginal community. An opportunity for managing co-morbidities?
    Vindigni D.
    Walker B.F.
    Jamison J.R.
    Da Costa C.
    Parkinson L.
    Blunden S.
    Chiropractic & Osteopathy, 13 (1):
  • [30] INCREASED RISK OF MORTALITY AND CO-MORBIDITIES IN PATIENTS WITH UNTREATED PRIMARY HYPERPARATHYROIDISM
    Yu, N.
    Leese, G. P.
    Donnan, P. T.
    VALUE IN HEALTH, 2009, 12 (07) : A311 - A311
12345